Application of kynurenic acid in treatment of chronic cirrhosis
By reducing the expression of specific genes and proteins in the liver, the problem of chronic cirrhosis treatment is solved, collagen deposition and pseudolobital formation are significantly alleviated, and effective treatment options for chronic cirrhosis are provided.
Patent Information
- Application Number
- CN202411248390.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-06
- Publication Date
- 2024-12-03
AI Technical Summary
The prior art lacks effective reversal treatment options to treat chronic cirrhosis, resulting in a lack of effective treatment methods for patients with cirrhosis.
Using kynulinic acid or its pharmaceutically acceptable salt or derivative, the liver can be inhibited by reducing the RNA and protein expression levels of α-SMA, Col1a1, Col3a1 and TIMP1 in the liver, thereby reducing collagen deposition and pseudo-lobitus formation. Progress of hardening.
Kynauric acid significantly reduced collagen deposition and pseudolobital formation in cirrhosis model mice, inhibited the progress of cirrhosis, and provided a new method to treat cirrhosis caused by chronic liver injury.
Smart Images

Figure BDA0005031539790000071 
Figure BDA0005031539790000121 
Figure BDA0005031539790000151
Abstract
Description
Technical Field
[0001] The invention relates to the field of biomedicine, and in particular to application of kynurenic acid in treating chronic liver cirrhosis. Background Art
[0002] Cirrhosis is a progressive, diffuse, chronic liver disease with diverse etiologies. Post-hepatitis cirrhosis is common in my country. In recent years, the incidence of alcoholic cirrhosis and non-alcoholic fatty cirrhosis has gradually increased. Its pathological characteristics include extensive hepatocyte degeneration and necrosis, collagen deposition in the liver, fibrous tissue proliferation, and destruction of pseudolobules and vascular structures. The proliferating fibrous cords re-divide the pseudolobules, leading to the formation of pseudolobules and gradually developing into liver fibrosis and even cirrhosis.
[0003] my country is a country with a high incidence of hepatitis and has a large number of patients with cirrhosis. Cirrhosis is the central link in the development of chronic liver disease and has many complications, among which esophageal varices and liver cancer are the main fatal complications. However, there is still a lack of effective reversal treatment options for cirrhosis.
[0004] Therefore, there is an urgent need in this field to develop more drugs that can effectively treat chronic liver cirrhosis. Summary of the invention
[0005] The purpose of the present invention is to provide a medicine which can effectively treat chronic liver cirrhosis.
[0006] In a first aspect of the present invention, there is provided a use of kynurenic acid, or a pharmaceutically acceptable salt thereof, or a derivative thereof in the preparation of a pharmaceutical composition for treating liver cirrhosis.
[0007] In another preferred embodiment, the cirrhosis is cirrhosis caused by chronic liver damage.
[0008] In another preferred embodiment, the liver cirrhosis is non-fatty liver-derived liver cirrhosis.
[0009] In another preferred embodiment, the chronic liver injury is chronic liver injury caused by chemical drugs or poisons.
[0010] In another preferred embodiment, the chronic liver damage is chronic liver damage caused by CCl4.
[0011] In another preferred embodiment, the liver cirrhosis comprises one or more characteristics selected from the following group compared with the normal state:
[0012] (i) increased expression levels of α-SMA, Col1a1, Col3a1, or TIMP1 RNA in the liver;
[0013] (ii) increased collagen deposition or pseudolobule formation in the liver;
[0014] (iii) Increased protein expression of α-SMA, Col1a1, Col3a1, or TIMP1.
[0015] In another preferred embodiment, the kynurenic acid is in a purified form.
[0016] In another preferred embodiment, the kynurenic acid is in the form of a pharmaceutical composition or veterinary composition containing a pharmaceutically acceptable excipient.
[0017] In another preferred embodiment, the amount of kynurenic acid, or a pharmaceutically acceptable salt thereof, or a derivative thereof is at least 100 mg / kg / d body weight calculated as the amount of KYNA.
[0018] In another preferred embodiment, the treatment of cirrhosis caused by chronic liver damage includes one or more characteristics selected from the following group:
[0019] (i) reducing the RNA expression level of α-SMA, Col1a1, Col3a1 or TIMP1 in the liver;
[0020] (ii) reduce collagen deposition or pseudolobule formation in the liver;
[0021] (iii) inhibiting liver cirrhosis;
[0022] (iv) inhibiting the protein expression of α-SMA, Col1a1, Col3a1 or TIMP1.
[0023] In a second aspect of the present invention, a pharmaceutical composition for treating liver cirrhosis caused by chronic liver damage is provided, the pharmaceutical composition comprising:
[0024] (z1) kynurenic acid, or a pharmaceutically acceptable salt thereof, or a derivative thereof as the first active ingredient;
[0025] (z2) a pharmaceutically acceptable carrier.
[0026] In another preferred embodiment, the pharmaceutical composition is administered to a subject selected from the group consisting of a rodent or a primate.
[0027] In another preferred embodiment, the subject is a subject not on a high-fat diet.
[0028] In another preferred embodiment, the subject is a non-diabetic patient.
[0029] In another preferred embodiment, the subject does not suffer from any of the following diseases:
[0030] (x1) Alcoholic fatty liver;
[0031] (x2) Non-alcoholic fatty liver disease.
[0032] In another preferred embodiment, the first active ingredient accounts for 1-99wt% of the total weight of the pharmaceutical composition; preferably, 10-90wt%; more preferably, 30-70wt%.
[0033] In another preferred embodiment, the pharmaceutical composition may be a single compound or a mixture of multiple compounds.
[0034] In another preferred embodiment, the dosage form of the pharmaceutical composition is an oral or parenteral dosage form.
[0035] In another preferred embodiment, the oral dosage form is a tablet, powder, granule or capsule, or an emulsion or syrup.
[0036] In another preferred embodiment, the non-oral dosage form is an injection or injection.
[0037] In another preferred embodiment, the dosage form of the pharmaceutical composition is selected from the following group: injection, inhalation, tincture, powder, granule, capsule, oral solution, tablet, pill, suspension, emulsion, lozenge, or pill.
[0038] In a third aspect of the present invention, a method for treating liver cirrhosis caused by chronic liver damage is provided, comprising the steps of:
[0039] A safe and effective amount of kynurenic acid, or a pharmaceutically acceptable salt thereof, or a derivative thereof, or a pharmaceutical composition containing them is administered to a subject in need, thereby treating liver cirrhosis caused by chronic liver damage.
[0040] In another preferred embodiment, the administration comprises oral administration.
[0041] In another preferred embodiment, the subject is a human or non-human mammal.
[0042] In another preferred embodiment, the non-human mammals include rodents and primates, preferably mice, rats, rabbits, and monkeys.
[0043] In another preferred embodiment, the administration time of kynurenic acid or a pharmaceutically acceptable salt thereof is 1-20 weeks, preferably 2-12 weeks, more preferably 4-8 weeks.
[0044] In another preferred embodiment, the dosage of kynurenic acid or a pharmaceutically acceptable salt thereof is 50 to 500 mg / kg / day, preferably 80 to 250 mg / kg / day, and more preferably 100 mg / kg / day.
[0045] In a fourth aspect of the present invention, a medicine kit is provided, comprising:
[0046] (I) a first formulation in a first container, the first formulation comprising (a) kynurenic acid, or a pharmaceutically acceptable salt thereof, or a derivative thereof as a first active ingredient, and (b) a pharmaceutically acceptable carrier;
[0047] (II) optionally a second formulation in a second container, the second formulation comprising as a second active ingredient another drug for treating liver cirrhosis; and
[0048] (III) instructions, wherein the instructions state that the medicine kit is used to treat liver cirrhosis caused by chronic liver damage.
[0049] In another preferred embodiment, the first preparation and the second preparation are independent of each other.
[0050] In another preferred embodiment, the first preparation is a lyophilized preparation or a liquid preparation.
[0051] In another preferred embodiment, the other drugs for treating liver cirrhosis include: nucleotide analogs, nitrates, calcium channel blockers, or a combination thereof.
[0052] In another preferred embodiment, the nucleotide analogs include lamivudine, adefovir dipivoxil, telbivudine, entecavir, tenofovir dipivoxil, clavudine, or a combination thereof.
[0053] In another preferred embodiment, the nitrates include isoflurane.
[0054] In another preferred embodiment, the calcium channel blocker includes nitroglycerin.
[0055] In a fifth aspect of the present invention, a kit is provided, comprising:
[0056] (1) a detection reagent for detecting pseudolobules;
[0057] (2) Kynurenic acid, or a pharmaceutically acceptable salt thereof, or a derivative thereof.
[0058] In another preferred embodiment, the pseudolobule detection reagent is a Sirius detection reagent.
[0059] In another preferred example, the kit is used to detect whether a subject has pseudolobule formation.
[0060] In another preferred embodiment, the kit further includes instructions, which state that a detection reagent is used to detect whether the subject has pseudolobule formation. If pseudolobule formation is detected, kynurenic acid, or a pharmaceutically acceptable salt thereof, or a derivative thereof is administered to the subject.
[0061] In the sixth aspect of the present invention, there is provided a use of the kit as described in the fifth aspect of the present invention, for preparing a companion diagnostic kit, wherein the companion diagnostic kit is used to determine whether a patient receiving treatment for liver cirrhosis should be treated with kynurenic acid, or a pharmaceutically acceptable salt thereof, or a derivative thereof.
[0062] In another preferred embodiment, the companion diagnostic kit is used to determine whether the patient is a patient with cirrhosis caused by chronic liver damage.
[0063] It should be understood that within the scope of the present invention, the above-mentioned technical features of the present invention and the technical features specifically described below (such as embodiments) can be combined with each other to form a new or preferred technical solution. Due to space limitations, they will not be described one by one here. BRIEF DESCRIPTION OF THE DRAWINGS
[0064] Figure 1 The gross image of the liver of mice with CCl4-induced chronic cirrhosis model is shown, wherein the mice were randomly divided into 3 groups: an olive oil control group (olive oil group), a CMC control solvent gavage for 2 weeks + CCl4 intraperitoneal injection for 8 weeks (CCl4 group), a 100 mg / kg KYNA gavage for 2 weeks + CCl4 group intraperitoneal injection for 8 weeks (CCl4+KYNA(100 mg / kg) group), wherein gavage of the above-mentioned reagent for 2 weeks means that the reagent is gavaged at the end of the 6th week of CCl4 intraperitoneal injection until the above-mentioned reagent is gavaged for 2 weeks, at which time CCl4 is intraperitoneally injected for 8 weeks; scale bar: 1 cm, 4 samples were selected from each group for photography.
[0065] Figure 2 Elisa detection of KYNA reduces the KYNA levels in portal vein serum (Figure A) and whole blood serum (Figure B) of mice with chronic liver cirrhosis induced by CCl4, n=5 in each group, all data are expressed as mean±standard deviation, *P<0.05, ***P<0.001.
[0066] Figure 3 RT-PCR detection showed that KYNA alleviated the expression of RNA levels of α-SMA (Figure A), Col1α1 (Figure B), Col3α1 (Figure C) and TIMP1 (Figure D) in CCl4-induced chronic cirrhosis model mice, n=5 in each group, all data are expressed as mean ± standard error, *P<0.05, **P<0.01.
[0067] Figure 4 Representative images of HE staining of liver tissue of mice model of chronic liver cirrhosis induced by CCl4 are shown, with magnifications of 40 times (upper figure), scale bar: 20 μm; and 100 times (lower figure), scale bar: 50 μm.
[0068] Figure 5 The results of Sirius red staining of liver tissue of mice with chronic liver cirrhosis model induced by CCl4 are shown, wherein Figure A shows a representative image of Sirius red staining of mouse liver tissue, wherein the red part in the figure represents the collagen deposition part, and the dotted box pointed by the arrow is the pseudolobule (the place wrapped by red collagen after staining is the pseudolobule); the magnifications are 40 times (upper figure) and 100 times (lower figure), respectively; Figure B is a statistical chart of the number of pseudolobules, n=5, and a 40X field of view was selected for each mouse for statistics; Figure C is a statistical chart of the Sirius red staining area and the percentage (%) of the total area under the field of view, wherein KYNA100 refers to 100 mg / kg KYNA; n=5 per group, all data are expressed as mean ± standard deviation, *P<0.05, **P<0.01, ***P<0.001.
[0069] Figure 6 The results of immunohistochemical detection of KYNA to alleviate CCl4-induced chronic cirrhosis model mouse liver tissue staining are shown, wherein, Figure A is a representative image of immunohistochemical detection of Col1a1 protein in mouse liver tissue, magnification: 100 times, scale bar: 50 microns; Figure B is a statistical graph of Figure A, n=5 in each group, all data are expressed as mean ± standard deviation, ***P<0.001; Figure C is a representative image of immunohistochemical detection of αSMA protein in mouse liver tissue, magnification: 100 times, scale bar: 50 microns; Figure D is a statistical graph of Figure C, wherein, KYNA100 refers to 100 mg / kg KYNA; n=5 in each group, all data are expressed as mean ± standard deviation, ***P<0.001.
[0070] Figure 7 The results of Western Blot detection show that KYNA alleviates the protein expression of Col1a1 (upper figure) and αSMA (lower figure) in CCL4-induced chronic liver cirrhosis model mice, n=3 in each group, where β-Actin represents the internal reference. DETAILED DESCRIPTION
[0071] After extensive and in-depth research, the inventor unexpectedly discovered for the first time that kynurenic acid can effectively treat cirrhosis caused by chronic liver damage. The present invention can effectively reduce the RNA expression levels of α-SMA, Col1a1, Col3a1 and TIMP1, inhibit the expression of α-SMA, Col1a1, Col3a1 and TIMP1 proteins, reduce inflammatory infiltration and collagen deposition, and thus reduce liver fibrosis and cirrhosis caused by chronic liver damage by administering kynurenic acid to mice with chronic liver cirrhosis induced by CCl4; the present invention uses Sirius red staining to verify that kynurenic acid can significantly reduce the formation of pseudolobules in the liver in chronic liver cirrhosis. On this basis, the inventor completed the present invention.
[0072] the term
[0073] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.
[0074] As used herein, the terms "pharmaceutical composition of the present invention", "drug of the present invention", "kynurenic acid", and "KYNA" can be used interchangeably and refer to a preparation or pharmaceutical composition containing kynurenic acid, or a pharmaceutically acceptable salt thereof, or a derivative thereof as an active ingredient.
[0075] As used herein, the terms "preparation combination", "preparation combination of the present invention" and "drug of the present invention" are used interchangeably and all refer to the pharmaceutical composition or kit described in the first aspect of the present invention.
[0076] As used herein, the term "comprising" or "including (comprising)" may be open, semi-closed and closed. In other words, the term also includes "consisting essentially of" or "consisting of".
[0077] As used herein, the term "subject", "subject in need" refers to any mammal or non-mammal. Mammals include, but are not limited to, humans, vertebrates such as rodents, non-human primates, cows, horses, dogs, cats, pigs, sheep, goats.
[0078] Cirrhosis
[0079] Cirrhosis is an important intermediate link in the development of chronic liver disease into liver cancer. Cirrhosis is a pathophysiological process and an important stage in the development of various chronic liver diseases into liver cancer. As a country with a high incidence of chronic liver disease, my country has a large population of people with cirrhosis, a long course of disease, many complications, and a poor prognosis. There is currently no reversal treatment. Therefore, methods for the treatment of cirrhosis are very important for the early prevention of liver cancer. Collagen deposition is very important in the process of cirrhosis. Studies have shown that the metabolites of intestinal flora are absorbed into the blood through the intestines, circulate to the portal vein, and enter the liver, which can reduce collagen deposition. The most direct and confirmed diagnosis is the formation of pseudolobules in the liver, which confirms the diagnosis of cirrhosis.
[0080] Pseudo-leaflet
[0081] In cirrhosis, the normal liver lobule structure is destroyed, and the extensively proliferated fibrous tissue separates the original liver lobules and wraps them into hepatocyte clusters of varying sizes, round or oval, called pseudolobules. Pseudolobules are different from normal liver lobules. The hepatocyte cords in pseudolobules are arranged in disorder, the central vein of the lobule is absent, offset, or there are more than two central veins, and sometimes the portal area that is wrapped in can be seen.
[0082] Kynurenic acid
[0083] Kynurenic acid (KYNA, molecular formula C 10 H7NO3) is a product of the kynurenine metabolic pathway in the metabolism of tryptophan. The structure is shown below:
[0084]
[0085] The present invention finds that kynurenic acid, or a pharmaceutically acceptable salt thereof, or a derivative thereof can treat liver cirrhosis, especially can treat liver cirrhosis caused by chronic liver damage.
[0086] Indications
[0087] The present invention relates to liver cirrhosis, especially liver cirrhosis caused by chronic liver damage. In one embodiment, the liver cirrhosis is liver cirrhosis derived from non-fatty liver, the chronic liver damage is chronic liver damage caused by chemical drugs or poisons, and the chronic liver damage is chronic liver damage caused by carbon tetrachloride (CCl4).
[0088] Pharmaceutical composition
[0089] The pharmaceutical composition provided by the present invention preferably contains 0.1-99 wt % of the first active ingredient, and the remainder is the second active ingredient, a pharmaceutically acceptable carrier, a diluent or a solution or a saline solution.
[0090] The first active ingredient of the present invention is kynurenic acid, or a pharmaceutically acceptable salt thereof, or a derivative thereof. In addition, it can also be used in combination with other therapeutic agents, namely, the second active ingredient.
[0091] The second active ingredient can be any drug ingredient capable of preventing and / or treating liver cirrhosis, including but not limited to interferon, nucleotide analogs, nitrates, calcium channel blockers, etc.
[0092] When necessary, one or more pharmaceutically acceptable carriers may be added to the drug of the present invention, including conventional diluents, excipients, fillers, binders, wetting agents, disintegrants, absorption promoters, surfactants, adsorption carriers, lubricants, etc. in the pharmaceutical field.
[0093] The compounds and pharmaceutical compositions provided by the present invention may be in various forms, such as tablets, injections, capsules, powders, syrups, solutions, suspensions and aerosols, and may be present in suitable solid or liquid carriers or diluents and in suitable sterile apparatus for injection or instillation.
[0094] The various dosage forms of the pharmaceutical composition of the present invention can be prepared according to conventional preparation methods in the pharmaceutical field. The unit dosage of the preparation formula generally contains 0.05-1000 mg of the active compound of the present invention, preferably, the unit dosage of the preparation formula contains 1 mg-500 mg of the active compound of the present invention.
[0095] The pharmaceutical composition of the present invention can be used clinically in mammals, including humans and animals, and can be administered through the mouth, nose, skin, lungs or gastrointestinal tract. Oral administration is the most preferred. The most preferred daily dose is 0.01-400 mg / kg body weight, taken at one time, or 0.01-200 mg / kg body weight taken in divided doses. Regardless of the method of administration, the optimal dose for an individual should be determined based on the specific treatment. Usually, a small dose is started and the dose is gradually increased until the most suitable dose is found.
[0096] The drugs or inhibitors of the present invention can be administered in various ways, for example, by injection, spraying, nasal drops, eye drops, penetration, absorption, physical or chemical mediated methods, such as introduction into the body into muscle, intradermal, subcutaneous, intravenous, mucosal tissue; or mixed or encapsulated in other substances and introduced into the body.
[0097] Typically, the active ingredient of the present invention or the pharmaceutical composition containing it can be administered in a unit dosage form, and the administration route can be enteral or parenteral, such as oral, intravenous, intramuscular, subcutaneous, nasal, oral mucosa, eyes, lungs and respiratory tract, skin, vagina, rectum, etc.
[0098] The dosage form can be a liquid dosage form, a solid dosage form or a semisolid dosage form. Liquid dosage forms can be solutions (including true solutions and colloidal solutions), emulsions (including O / W types, W / O types and multiple emulsions), suspensions, injections (including water injections, powder injections and infusions), eye drops, nasal drops, lotions and liniments, etc.; solid dosage forms can be tablets (including ordinary tablets, enteric-coated tablets, lozenges, dispersible tablets, chewable tablets, effervescent tablets, orally disintegrating tablets), capsules (including hard capsules, soft capsules, enteric-coated capsules), granules, powders, micropills, dropping pills, suppositories, films, patches, aerosols (powders), sprays, etc.; semisolid dosage forms can be ointments, gels, pastes, etc.
[0099] The active ingredients of the present invention can be made into common preparations, sustained-release preparations, controlled-release preparations, targeted preparations and various microparticle drug delivery systems.
[0100] In order to prepare the active ingredients of the present invention into tablets, various excipients known in the art can be widely used, including diluents, binders, wetting agents, disintegrants, lubricants, and glidants. The diluent may be starch, dextrin, sucrose, glucose, lactose, mannitol, sorbitol, xylitol, microcrystalline cellulose, calcium sulfate, calcium hydrogen phosphate, calcium carbonate, etc.; the wetting agent may be water, ethanol, isopropanol, etc.; the adhesive may be starch slurry, dextrin, syrup, honey, glucose solution, microcrystalline cellulose, acacia slurry, gelatin slurry, sodium carboxymethyl cellulose, methyl cellulose, hydroxypropyl methyl cellulose, ethyl cellulose, acrylic resin, carbomer, polyvinyl pyrrolidone, polyethylene glycol, etc.; the disintegrant may be dry starch, microcrystalline cellulose, low-substituted hydroxypropyl cellulose, cross-linked polyvinyl pyrrolidone, cross-linked sodium carboxymethyl cellulose, sodium carboxymethyl starch, sodium bicarbonate and citric acid, polyoxyethylene sorbitan fatty acid ester, sodium dodecyl sulfate, etc.; the lubricant and glidant may be talc, silicon dioxide, stearate, tartaric acid, liquid paraffin, polyethylene glycol, etc.
[0101] The tablets can be further made into coated tablets, such as sugar-coated tablets, film-coated tablets, enteric-coated tablets, or double-layer tablets and multi-layer tablets.
[0102] In order to prepare the dosing unit into a capsule, the active ingredient of the present invention can be mixed with a diluent and a glidant, and the mixture can be directly placed in a hard capsule or a soft capsule. The active ingredient can also be first made into granules or pellets with a diluent, a binder, and a disintegrant, and then placed in a hard capsule or a soft capsule. The diluents, binders, wetting agents, disintegrants, and glidants used to prepare the tablets of the present invention can also be used to prepare the capsules of the present invention.
[0103] To prepare the active ingredient of the present invention into an injection, water, ethanol, isopropanol, propylene glycol or a mixture thereof can be used as a solvent and an appropriate amount of a solubilizer, a cosolvent, a pH adjuster, and an osmotic pressure regulator commonly used in the art can be added. The solubilizer or cosolvent can be poloxamer, lecithin, hydroxypropyl-β-cyclodextrin, etc.; the pH adjuster can be phosphate, acetate, hydrochloric acid, sodium hydroxide, etc.; the osmotic pressure regulator can be sodium chloride, mannitol, glucose, phosphate, acetate, etc. If a lyophilized powder injection is prepared, mannitol, glucose, etc. can also be added as a support agent.
[0104] Furthermore, if necessary, colorants, preservatives, perfumes, flavoring agents or other additives may be added to the pharmaceutical preparations.
[0105] The active ingredient or composition of the present invention can be taken alone or in combination with other therapeutic drugs or symptomatic drugs.
[0106] When the active ingredient of the present invention has a synergistic effect with other therapeutic drugs, its dosage should be adjusted according to the actual situation.
[0107] It should be understood that the effective amount of the active ingredient of the present invention may vary with the mode of administration and the severity of ischemic stroke. The selection of the preferred effective amount can be determined by a person of ordinary skill in the art based on various factors (e.g., through clinical trials). The factors include, but are not limited to: pharmacokinetic parameters such as bioavailability, metabolism, half-life, etc.; severity, patient's weight, patient's immune status, route of administration, etc.
[0108] There is no particular limitation on the administration method of the pharmaceutical preparation of the present invention. Representative examples include (but are not limited to): oral administration, intravenous injection, intracranial injection, subcutaneous injection, intramuscular injection or nasal drip.
[0109] Furthermore, the present invention also provides a medicine box, which comprises:
[0110] (I) a first formulation in a first container, the first formulation comprising (a) kynurenic acid, or a pharmaceutically acceptable salt thereof, or a derivative thereof as a first active ingredient, and (b) a pharmaceutically acceptable carrier;
[0111] (II) optionally a second formulation in a second container, the second formulation comprising as a second active ingredient another drug for treating liver cirrhosis; and
[0112] (III) instructions, wherein the instructions state that the medicine kit is used to treat liver cirrhosis caused by chronic liver damage.
[0113] Furthermore, the present invention provides a method for treating cirrhosis caused by chronic liver damage, the method comprising the steps of administering a safe and effective amount of kynurenic acid, or a pharmaceutically acceptable salt thereof, or a derivative thereof, or a pharmaceutical composition comprising them to a subject in need, thereby treating cirrhosis caused by chronic liver damage.
[0114] The subject suitable for the present invention is a human or a non-human mammal (such as a rat, a mouse or a monkey).
[0115] The technical solution of the present invention has the following main advantages:
[0116] (1) The present invention provides the use of kynurenic acid, or a pharmaceutically acceptable salt thereof, or a derivative thereof in the preparation of a drug for treating cirrhosis caused by chronic liver damage. The present invention can effectively reduce the RNA expression levels of α-SMA, Col1a1, Col3a1 and TIMP1, inhibit α-SMA and Col1a1, reduce inflammatory infiltration and collagen deposition, and thus reduce cirrhosis caused by chronic liver damage by administering kynurenic acid to mice with chronic liver cirrhosis induced by CCl4.
[0117] (2) The present invention uses Sirius red staining to verify that kynurenic acid can significantly reduce the formation of pseudolobules in the liver in chronic liver cirrhosis.
[0118] (3) The present invention reveals that kynurenic acid significantly inhibits the progression of chronic liver cirrhosis.
[0119] (3) The present invention provides a new method for treating cirrhosis caused by chronic liver damage, and provides a new idea for the treatment of chronic cirrhosis.
[0120] (4) The method for treating liver cirrhosis caused by chronic liver damage provided by the present invention is simple to operate, and the preparation of the drug for treating liver cirrhosis caused by chronic liver damage is simple and efficient.
[0121] The present invention will be further described below in conjunction with specific examples. It should be understood that these examples are only used to illustrate the present invention and are not intended to limit the scope of the present invention. The experimental methods in the following examples where specific conditions are not specified are usually carried out under conventional conditions such as those described in Sambrook et al., Molecular Cloning: A Laboratory Manual (New York: Cold Spring Harbor Laboratory Press, 1989), or according to the conditions recommended by the manufacturer. Unless otherwise stated, percentages and parts are calculated by weight. The experimental materials and reagents involved in the present invention can be obtained from commercial channels unless otherwise specified.
[0122] Example 1
[0123] The present invention determines the sample size by performing power calculation of mean square error and standard deviation on the main parameters (power value = 80%, α = 0.05). The results are expressed as mean ± standard deviation (SD). First, the Kolmogorov-Smirnov normality test is performed on all data sets. For normally distributed continuous variables, the two groups are compared using a two-tailed Student's t test (equal variance) or Welch's t test (unequal variance), and multiple groups are compared using a one-way variance analysis (ANOVA), followed by a Bonferroni multiple comparison test or a two-way variance analysis. Repeated measures variance analysis is used to analyze the differences in the means of groups repeatedly measured over time. When the variance analysis shows a significant difference, a post hoc Bonferroni (comparison between all conditions) and a Dunnett (comparison of all conditions with a control group) test are used for pairwise comparisons of the means. For non-normally distributed continuous variables or non-continuous variables, a two-tailed Mann-Whitney U rank sum test is used. In all analyses, p < 0.05 was considered statistically significant. All statistics were performed using GraphPad Prism (v.9.0.0). The specific experiments are as follows:
[0124] 1. CCl4-induced chronic liver cirrhosis model in mice and its collection
[0125] 6-7 week old male C57BL / 6 mice (purchased from Shanghai Paijieluo Technology Co., Ltd.) were divided into three groups. One group was intraperitoneally injected with olive oil as the control group, and the other two groups were intraperitoneally injected with CCl4 (0.5ml / kg, CCl4:olive oil=1:9, intraperitoneally injected twice a week) for a total of eight weeks. At the end of the sixth week of modeling, KYNA was dissolved in 0.5% CMC and gavaged at a concentration of 100 mg / kg to one group of the CCl4 modeling group (hereinafter referred to as CCl4+KYNA100), and the control group CCl4 and olive oil groups were gavaged with 0.5% CMC (hereinafter referred to as Oil group and CCl4 group), and gavage was performed daily for a total of 2 weeks. In the eighth week, the mice were killed, portal vein blood and inferior vena cava blood were collected, and the liver was exposed and completely removed. The right liver was embedded in paraffin, and the left liver was used for RNA and protein extraction for subsequent RT-PCR and Western blot verification.
[0126] like Figure 1 As shown in the figure, mice with chronic liver cirrhosis model were established by intraperitoneal injection of CCl4, and the mice were randomly divided into 3 groups: olive oil control group (olive oil group), CMC control solvent gavage + CCl4 group (CCl4 group), 100 mg / kg KYNA gavage + CCl4 group (called CCl4+KYNA (100 mg / kg) group, abbreviated as CCl4+KYNA group). Compared with the olive oil group, the liver in the CCl4 group had obvious adhesion to the surrounding tissues, the liver edge was rounded, and the liver surface showed diffuse small nodules; compared with the CCl4 modeling group, the diffuse small nodules on the liver surface in the CCl4+KYNA group were reduced.
[0127] 2. Elisa detection of serum KYNA concentration in CCl4-induced chronic liver cirrhosis model mice
[0128] After the portal vein blood collected above was placed at 4°C overnight, centrifuged at 4°C, 3000rpm, for 15 minutes the next day, and the supernatant was taken. The enzyme-linked biological KYNA Elisa detection kit (ml049033) was used and operated according to its instructions, wherein 10 μL of serum was diluted to 50 μL with sample diluent, incubated with horseradish peroxidase-labeled antibody at 37°C for 1 hour, and then washed 5 times. 100 μL of color development solution was added to each well, incubated at 37°C in the dark for 15 minutes, and then 50 μL of stop liquid was added, and the KYNA concentration was determined by reading the absorbance photometer at 450nm.
[0129] The results are as follows Figure 2As shown in the figure, compared with the normal group, the KYNA concentration in the portal vein serum of mice in the CCl4 group was reduced, and there was a statistically significant difference (p<0.001), indicating that KYNA had a downward trend in the portal vein serum of mice with chronic liver cirrhosis induced by CCl4; compared with the mice in the CCl4 group, the KYNA concentration in the portal vein serum of mice in the CCl4+KYNA group was significantly increased ( Figure 2 A). Similarly, the KYNA concentration in the whole serum of mice with chronic liver cirrhosis induced by CCl4 also increased significantly, indicating that oral administration of 100 mg / kg KYNA can increase the KYNA level in the serum of mice with chronic liver cirrhosis induced by CCl4 ( Figure 2 B).
[0130] 3. Real time-PCR (RT-PCR) detection of changes in liver cirrhosis indicators in mice
[0131] (1) RNA extraction
[0132] Add 1mL Trizol (RNAiso Plus) to the liver tissue obtained in the above experiment 1, let it stand for 5 minutes, then blow it with a pipette and collect it in the imported Eppendorf centrifuge tube. Add 0.2mL chloroform (one-fifth of the volume of Trizol), cover tightly, and shake it thoroughly for 15s until it is fully emulsified. Let it stand at room temperature for 5min (at this time, adjust the centrifuge to 4℃ and 12,000g for preparation). Centrifuge at 4℃ and 12,000g for 15min. Take the upper transparent band, add 0.4mL isopropanol (the same volume as the supernatant sucked out from the top), mix it up and down slowly 5 times, and let it stand at room temperature for 10min. Centrifuge at 4℃ and 12,000g for 10min. When a precipitate is visible at the bottom, discard the supernatant.
[0133] Gently add 1mL of 75% ethanol (prepared with DEPC water), bounce the RNA precipitate, rinse, centrifuge at 4℃, 7,500g for 5min, and aspirate the supernatant as thoroughly as possible to prevent the loss of RNA precipitate. Invert the EP tube to dry the water droplets on the tube wall, dissolve the dried RNA in 30μL of DEPC water, measure the OD260 / 280 value with a spectrophotometer, prepare the working concentration (1μg / μL), and detect the RNA integrity by 1% agarose gel electrophoresis, and store at -80℃ for later use.
[0134] (2) Reverse transcription reaction
[0135] Reverse transcription uses TAKARA kit, 10μL system reverses 1000ng RNA, taking the reverse 1μg, 20μL system as an example, take the reverse transcription kit reagents 1, 2, 3. Measure the concentration of each RNA and calculate the amount required for 1μg of RNA. Take a common eight-link PCR tube and add the system: 5× Primescript PT Enzyme MIX (4μL), Total RNARNase Free ddH20 (up to 20μL). Perform reverse transcription on a common PCR instrument, 37℃ for 15 minutes, 85℃ for 30 seconds, 4℃ forever.
[0136] (3) real time-PCR
[0137] Take a 1.5ml EP tube and prepare a MIX of 2×TB Green, primers, and ddH2O. Prepare 6μL MIX in each well: 2×TB Green (5μL), primers (as shown in Table 1 below, 0.3μL each for positive and negative), and 0.4μL ddH2O. Dispense the MIX into the real-time plate, 6μL per well, and operate on ice.
[0138] Then add 4 μL of the corresponding diluted template to each well, with a total volume of 10 μL per well, and then put it on the machine.
[0139] (4) Primer sequence
[0140] Table 1 shows the primer sequences used for RT-PCR.
[0141] Table 1
[0142]
[0143] Note: mmu refers to mouse, which means the primers are suitable for identifying gene expression in the mouse species.
[0144] The results are as follows Figure 3 As shown in the figure, RT-PCR experiments showed that compared with the normal group, the mice in the CCl4 group showed higher levels of α-SMA, Col1α1, Col3α1, and TIMP1 RNA levels, indicating that CCl4 successfully established a mouse cirrhosis model ( Figure 3 A-3D).
[0145] Compared with the mice in the CCl4 group, the RNA levels of α-SMA, Col1α1, Col3α1, and TIMP1 in the mice in the CCl4+KYNA group were significantly decreased ( Figure 3 A-3D), indicating that KYNA has an in vivo inhibitory effect on mouse liver cirrhosis.
[0146] 4. HE staining to detect changes in liver tissue of CCL4-induced chronic liver cirrhosis model mice
[0147] The paraffin-embedded liver tissue obtained in 1 above was cut into 0.4 μm slices, and then dewaxed in xylene three times, each for 15 minutes. The dewaxed slices were hydrated with gradient alcohol (100%, 95%, 85%, 75%, each for 3 minutes), washed three times with PBS, stained with hematoxylin for 1 minute, eosin for 30 seconds, washed three times with PBS, dried, and sealed with neutral resin.
[0148] The results are as follows Figure 4 As shown, compared with the normal group, the livers of mice in the CCl4 group showed obvious inflammatory infiltration; compared with the CCl4 group, the CCl4+KYNA group could significantly reduce the CCl4 inflammatory infiltration, indicating that KYNA can significantly reduce the inflammatory infiltration of CCl4-induced chronic cirrhosis model mice after 14 days of oral administration.
[0149] 5. Detection of collagen deposition and pseudolobule formation in the liver of CCL4-induced chronic liver cirrhosis model mice by Sirius red staining
[0150] The paraffin-embedded tissue obtained in the above experiment 1 was cut into 0.4 μm slices. The slices were dewaxed in xylene three times, each for 15 minutes. The dewaxed slices were hydrated with gradient alcohol (100%, 95%, 85%, 75%, 3 minutes each time), washed three times with PBS, and stained with Sirius red drop solution for 1 hour. After 1 hour, they were washed once with PBS, dried, and sealed with neutral resin.
[0151] The results are as follows Figure 5 As shown in the figure, compared with the normal group, the mice in the CCl4 group showed obvious collagen deposition (the red part in the figure is collagen) and the formation of pseudolobules ( Figure 5 A, the dotted box indicated by the arrow is the pseudolobule), and the semi-quantitative statistical results using image j in the same field of view showed that under a 40x microscope, the mice treated with KYNA could clearly see a decrease in collagen deposition, and the number of pseudolobules in the same field of view was counted. Compared with the CCl4 group, the number of pseudolobules in the CCl4-induced liver cirrhosis model mice treated with KYNA was significantly reduced, with a statistically significant difference ( Figure 5 B). KYNA can significantly reduce the Sirius red staining area of liver tissue in CCl4-induced chronic liver cirrhosis model mice, with statistically significant difference ( Figure 5 C).
[0152] 6. Immunohistochemical staining to detect the expression of Col1a1 and α-SMA proteins in the liver of CCl4-induced chronic liver cirrhosis model mice
[0153] The paraffin-embedded tissue obtained in 1 above was cut into 0.4 μm slices. The slices were dewaxed in xylene three times, each for 15 minutes. The dewaxed slices were hydrated with gradient alcohol (100%, 95%, 85%, 75%, 3 minutes each time), and then washed with PBS three times. Antigen repair (acid repair or alkali repair) was boiled in water (300w power) for 20 minutes; after natural cooling, it was washed twice with double distilled water, and then a water blocking circle was drawn with a water blocking pen. Washed with PBS three times, 5 minutes each time. 0.3% H202 was added to the tissue to remove peroxidase in the tissue for 10 minutes. Rinse and soak in PBST three times, 5 minutes each time. After blocking with 10% goat serum for 1 hour, incubate with α-SMA (ABclonal, A2235) and Col1a1 (CST, 72026) primary antibodies at 4°C overnight. The next day, after washing with PBST for 3 times, incubate with secondary antibody (Gene Technology, GK500710) for 1 hour. Prepare DAB mixed solution for color development. Stop the reaction when brown particles appear under the microscope. After counterstaining with hematoxylin for 20 seconds, differentiate with hydrochloric acid alcohol for a few seconds, and then turn blue with warm water for a few seconds. Dry and dehydrate in a 65℃ oven, and seal with neutral resin.
[0154] The results are as follows Figure 6 As shown, α-SMA ( Figure 6 A and Figure 6 B) and Col1a1( Figure 6 C and Figure 6 D) increased significantly in the interstitium, and KYNA administration for 2 weeks significantly reduced the expression of α-SMA ( Figure 6 A and Figure 6 B) and Col1a1( Figure 6 C and Figure 6 D) Deposition in the interstitium. The above results indicate that KYNA significantly inhibits CCl4-induced chronic liver cirrhosis.
[0155] 7. Western Blot detection of changes in Col1a1 and α-SMA protein levels in the liver of CCL4-induced chronic liver cirrhosis model mice
[0156] The liver tissue obtained in 1 above was lysed with 2× lysis buffer, mixed vigorously, and then placed in a water bath for 15 minutes. Centrifuge at 12000rpm, room temperature for 5 minutes, take the supernatant for further BCA protein quantification, and after measuring the protein content, calculate the volume of the solution containing 80μg protein for loading, which is the loading amount. After preparing 10% separation gel and 4% concentrated gel, prepare the electrophoresis solution (Tris (MW121.14) 3.02g, glycine (MW75.07) 14.4g, SDS1g, add distilled water to 1000mL). After adding enough electrophoresis solution, start preparing for loading, the voltage is 80V, and adjust the voltage to 120V after bromophenol blue runs to the lower layer of gel. Electrophoresis can be terminated when bromophenol blue just runs out, and transfer to the membrane. Use the wet transfer method, set a constant current of 250mA, and the transfer can be completed in 90min. After the transfer, the membrane was moved to a plate containing blocking solution (5% w / v skim milk) and blocked on a decolorizing shaker at room temperature for 1 hour. Dilute the primary antibody with blocking solution to an appropriate concentration (in a 1.5mL centrifuge tube); drop the antibody solution onto the PVF-wrapped glass plate, place it in a wet box, and place the membrane protein side down on the antibody liquid surface at 4°C overnight. The next day, wash twice with 0.1% PBST (Tween20+PBS) on a decolorizing shaker at room temperature for 10 minutes each time. Prepare the secondary antibody dilution and contact it with the membrane. After incubation at room temperature for 1 hour, wash twice with PBST on a decolorizing shaker at room temperature for 10 minutes each time, and scan the membrane. Table 2 shows the information of the primary and secondary antibodies used.
[0157] Table 2
[0158]
[0159] The results are as follows Figure 7 As shown in the results, intraperitoneal injection of CCl4 for 8 weeks successfully increased the protein expression of Col1a1 and α-SMA in the liver of mice, and the increase in Col1a1 and α-SMA protein levels caused by CCl4 could be inhibited by KYNA. Therefore, KYNA can significantly inhibit the key proteins Col1a1 and α-SMA in the progression of liver cirrhosis in mice, thereby alleviating liver cirrhosis.
[0160] The above results indicate that KYNA can reduce inflammatory infiltration and collagen deposition in cirrhotic mice, significantly inhibit fibrosis in vivo, and thus inhibit the progression of liver fibrosis to cirrhosis.
[0161] discuss
[0162] In recent years, the tryptophan metabolic pathway is a related amino acid pathway that has been studied more in liver disease, and its metabolites are closely related to the progression of acute and chronic liver diseases. In the study by Wei XL et al. (Wei X, Yin F, Wu M, et al. G protein-coupled receptor 35 attenuates nonalcoholic steatohepatitis by reprogramming cholesterol homeostasis in hepatocytes. Acta Pharm Sin B. 2023; 13(3): 1128-1144.), it was found that 5 mg / kg KYNA, as an agonist of G Protein-Coupled Receptor 35 (GPR35), can alleviate the damage and inflammatory infiltration of hepatocytes in fatty liver hepatitis induced by high fat and high cholesterol, and improve liver function and liver fibrosis.
[0163] The present invention shows that 100 mg / kg / d KYNA can reduce the expression of fiber-related genes and proteins in the CCl4-induced cirrhosis model, reduce collagen deposition, and significantly reduce the formation of pseudolobules, and has a preventive and / or therapeutic effect on cirrhosis caused by chronic liver damage.
[0164] Unlike the above, liver fibrosis is the early stage of liver cirrhosis, and the pharmaceutical composition of the present invention can play a therapeutic role in the liver cirrhosis stage. In addition, unlike metabolic fatty liver disease, the accumulation of cholesterol and lipids in the liver cirrhosis model caused by the poison of the present invention is less, and can play a different role.
[0165] All documents mentioned in the present invention are cited as references in this application, just as each document is cited as reference individually. In addition, it should be understood that after reading the above teachings of the present invention, those skilled in the art can make various changes or modifications to the present invention, and these equivalent forms also fall within the scope defined by the claims attached to this application.
Claims
1. Use of kynurenic acid, or a pharmaceutically acceptable salt thereof, or a derivative thereof in preparing a pharmaceutical composition for treating liver cirrhosis.
2. The use according to claim 1, characterized in that The liver cirrhosis is liver cirrhosis caused by chronic liver damage.
3. The use according to claim 1, characterized in that The cirrhosis comprises one or more characteristics selected from the following group compared to the normal state: (i) increased expression levels of α-SMA, Col1a1, Col3a1, or TIMP1 RNA in the liver; (ii) increased collagen deposition or pseudolobule formation in the liver; (iii) Increased protein expression of α-SMA, Col1a1, Col3a1, or TIMP1.
4. The use according to claim 1, characterized in that The amount of kynurenic acid, or a pharmaceutically acceptable salt thereof, or a derivative thereof used is at least 100 mg / kg / d body weight calculated as the amount of KYNA used.
5. A pharmaceutical composition for treating liver cirrhosis caused by chronic liver damage, the pharmaceutical composition comprising: (z1) kynurenic acid, or a pharmaceutically acceptable salt thereof, or a derivative thereof as the first active ingredient; (z2) a pharmaceutically acceptable carrier.
6. The pharmaceutical composition according to claim 5, characterized in that The dosage form of the pharmaceutical composition is an oral administration form or a parenteral administration form.
7. A medicine box, characterized in that: The kit comprises: (I) a first formulation in a first container, the first formulation comprising (a) kynurenic acid, or a pharmaceutically acceptable salt thereof, or a derivative thereof as a first active ingredient, and (b) a pharmaceutically acceptable carrier; (II) optionally a second formulation in a second container, the second formulation comprising another drug for treating liver cirrhosis as a second active ingredient; and (III) instructions, wherein the instructions state that the medicine kit is used to treat liver cirrhosis caused by chronic liver damage.
8. A kit, comprising: (1) a detection reagent for detecting pseudolobules; (2) Kynurenic acid, or a pharmaceutically acceptable salt thereof, or a derivative thereof.
9. The kit according to claim 8, characterized in that The kit also includes instructions, which state that a detection reagent is used to detect whether a subject has pseudolobule formation. If pseudolobule formation is detected, kynurenic acid, or a pharmaceutically acceptable salt thereof, or a derivative thereof is administered to the subject.
10. Use of the kit according to claim 8, for preparing a companion diagnostic kit, wherein the companion diagnostic kit is used to determine whether a patient with liver cirrhosis should be treated with kynurenic acid, or a pharmaceutically acceptable salt thereof, or a derivative thereof.
Citation Information
Patent Citations
Application of kynurenic acid in preparation of medicine for preventing and treating intestinal ischemia-reperfusion injury
CN118319911A
Anti-Fibrogenic Compounds, Methods and Uses Thereof
US20160120857A1
